UBS upgrades this kidney treatment stock, says it could rally 30%
The firm upgraded shares to buy and raised its price target to a Street-high of $142, citing an upcoming inflection in treatment growth.
Source link
The firm upgraded shares to buy and raised its price target to a Street-high of $142, citing an upcoming inflection in treatment growth.
Source link
/cloudfront-us-east-2.images.arcpublishing.com/reuters/2B4ZUADSDRP5XEBTOCVSHXMUWY.jpg "Concerns over COVID variant trigger more travel curbs on southern Africa"){kind=small}